Get the Stockscreener App
15.47
0.51%
-0.08
After Hours:
15.51
0.04
+0.26%
Summit Therapeutics Inc stock is traded at $15.47, with a volume of 3.20M.
It is down -0.51% in the last 24 hours and down -5.96% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$15.55
Open:
$15.46
24h Volume:
3.20M
Relative Volume:
0.64
Market Cap:
$12.34B
Revenue:
$220.00K
Net Income/Loss:
$-1.21B
P/E Ratio:
-9.6452
EPS:
-1.6039
Net Cash Flow:
$-387.48M
1W Performance:
+5.74%
1M Performance:
-5.96%
6M Performance:
-30.53%
1Y Performance:
-17.49%
1-Day Range:
$15.07
$15.55
1-Week Range:
$14.83
$16.35
52-Week Range:
$12.07
$29.23
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
15.47 | 12.34B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-26 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-26 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Aug-12-26 | Upgrade | Leerink Partners | Underperform → Market Perform |
| May-22-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-08-26 | Initiated | Stifel | Buy |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-17-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Underweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Neutral |
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Summit Expands Ivonescimab Development Into Biliary Tract Cancer - Zacks Investment Research
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? - Zacks Investment Research
For distant-stage biliary cancer, estimated five-year survival is under 5%. Summit plans a drug-combination trial. - Stock Titan
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma - Investing News Network
A share-increase proposal at Summit Therapeutics (SMMT) would help enable conversion of $2B in preferred stock. - Stock Titan
Accounting chief gets a stock grant at Summit Therapeutics (SMMT), vesting in 2029 if still employed. - Stock Titan
Summit Therapeutics Inc Stock (SMMT) Moved Down by 8.61% on Oct 13: Key Drivers Unveiled - TradingKey
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics - citybiz
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos - Zacks Investment Research
Summit Therapeutics (NasdaqGM:SMMT) Stock Forecast & Analyst Predictions - Simply Wall Street
AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up - Yahoo Finance
Summit Therapeutics Stock Climbs Wednesday: What's Happening? - Benzinga
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets - 24/7 Wall St.
Summit Therapeutics secures major AstraZeneca equity partnership - The Globe and Mail
AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets - Yahoo Finance
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics - Pharmaceutical Executive
AstraZeneca Invests $2B in Summit for Cancer Drug Dev - Rediff MoneyWiz
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab - Benzinga
Summit Therapeutics Shares Rise 22% After $2 Billion AstraZeneca Investment - Yahoo Finance
Summit Therapeutics Raises $2.0 Billion in Convertible Preferred Private Placement With AstraZeneca - TradingView
AstraZeneca invests $2bn in Summit Therapeutics to develop cancer drug - Business Weekly
Summit snags $2B investment from AstraZeneca, clearing financial overhang - BioSpace
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - Reuters
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Proactive financial news
Summit Therapeutics agrees to US$2B AstraZeneca equity investment - Mugglehead Investment Magazine
AstraZeneca invests $2 billion in Summit Therapeutics By Investing.com - Investing.com
Summit Therapeutics rises after AstraZeneca commits $2B investment - TradingView
AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer - AstraZeneca
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics - Business Wire
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Yahoo Finance UK
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Yahoo Finance
Summit Therapeutics (SMMT) Shows Promising Trial Results but Faces Valuation Challenges - GuruFocus
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics (SMMT) Gains Attention as Phase III Trial Data Boosts Outlook Amid Valuation Challenges - GuruFocus
Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com South Africa
Summit Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com
Summit Therapeutics shares gain after Jefferies upgrades stock to Buy - Yahoo Finance
Summit Therapeutics stock surges on Jefferies upgrade to buy By Investing.com - Investing.com Canada
Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com Canada
Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com UK
Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 61.45% Upside - DirectorsTalk Interviews
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress - Yahoo Finance
Ivonescimab Demonstrates an Overall Survival Benefit in Advanced NSCLCSummit Therapeutics - Oncodaily
Why Summit Therapeutics (SMMT) Is Up 19.5% After New Ivonescimab Phase III Survival DataAnd What's Next - simplywall.st
Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S. (SMMT) - Seeking Alpha
Why is Summit Therapeutics stock surging today? By Investing.com - Investing.com South Africa
Summit's Ivonescimab Beats Merck's Keytruda on Survival in Chinese Lung Cancer Trial - finance.biggo.com
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug - Barron's
Why Is Summit Therapeutics Stock Soaring Today?Summit Therapeutics (NASDAQ:SMMT) - Benzinga
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - benzinga.com
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Summit Therapeutics Inc Stock (SMMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 12 '26 |
Buy |
13.12 |
3,810,000 |
49,987,200 |
573,883,879 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Soni Manmeet Singh | COO and CFO |
Jun 04 '26 |
Buy |
14.45 |
50,000 |
722,250 |
3,123,603 |
| Xia Yu | Director |
Oct 21 '25 |
Buy |
18.74 |
533,617 |
9,999,983 |
32,057,147 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
0.10%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):